- Home
- TRVI vs GBAB Comparison
TRVI vs GBAB Comparison
Compare TRVI & GBAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- GBAB
- Stock Information
- Founded
- TRVI 2011
- GBAB 2010
- Country
- TRVI United States
- GBAB United States
- Employees
- TRVI N/A
- GBAB N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- GBAB Investment Managers
- Sector
- TRVI Health Care
- GBAB Finance
- Exchange
- TRVI Nasdaq
- GBAB Nasdaq
- Market Cap
- TRVI 383.4M
- GBAB 409.5M
- IPO Year
- TRVI 2019
- GBAB N/A
- Fundamental
- Price
- TRVI $6.61
- GBAB $15.24
- Analyst Decision
- TRVI Strong Buy
- GBAB
- Analyst Count
- TRVI 8
- GBAB 0
- Target Price
- TRVI $17.56
- GBAB N/A
- AVG Volume (30 Days)
- TRVI 1.3M
- GBAB 69.4K
- Earning Date
- TRVI 05-08-2025
- GBAB 01-01-0001
- Dividend Yield
- TRVI N/A
- GBAB 9.18%
- EPS Growth
- TRVI N/A
- GBAB N/A
- EPS
- TRVI N/A
- GBAB N/A
- Revenue
- TRVI N/A
- GBAB N/A
- Revenue This Year
- TRVI N/A
- GBAB N/A
- Revenue Next Year
- TRVI N/A
- GBAB N/A
- P/E Ratio
- TRVI N/A
- GBAB N/A
- Revenue Growth
- TRVI N/A
- GBAB N/A
- 52 Week Low
- TRVI $2.30
- GBAB $14.22
- 52 Week High
- TRVI $7.39
- GBAB $17.44
- Technical
- Relative Strength Index (RSI)
- TRVI 56.38
- GBAB 50.39
- Support Level
- TRVI $6.37
- GBAB $15.13
- Resistance Level
- TRVI $7.24
- GBAB $15.36
- Average True Range (ATR)
- TRVI 0.42
- GBAB 0.15
- MACD
- TRVI -0.01
- GBAB 0.02
- Stochastic Oscillator
- TRVI 50.38
- GBAB 54.39
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About GBAB Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust of Beneficial Interest
Guggenheim Taxable Municipal Managed Duration Trust is a diversified closed-end management investment company. Its investment objective is to provide current income with a secondary objective of long-term capital appreciation. Its products include Mutual funds, Unit investment trusts, Closed-end funds, Rydex funds, Credit income fund and others.